Abstract
The design and synthesis of dual PPAR gamma/delta agonist (R)-3-{2-ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}propionic acid is described. This compound dose-dependently lowered plasma glucose in hyperglycemic male Zucker diabetic fatty (ZDF) rats and produced less weight gain relative to rosiglitazone at an equivalent level of glucose control.
MeSH terms
-
Animals
-
Blood Glucose / metabolism
-
Dose-Response Relationship, Drug
-
Drug Design
-
Female
-
Half-Life
-
Humans
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / pharmacology*
-
Indicators and Reagents
-
Insulin / blood
-
Male
-
PPAR delta / agonists*
-
PPAR gamma / agonists*
-
Rats
-
Rats, Sprague-Dawley
-
Rats, Zucker
-
Rosiglitazone
-
Structure-Activity Relationship
-
Thiazolidinediones / pharmacology
-
Weight Gain / drug effects
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
Indicators and Reagents
-
Insulin
-
PPAR delta
-
PPAR gamma
-
Thiazolidinediones
-
Rosiglitazone